A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair
Abstract C1QBP exhibits heightened expression across a spectrum of tumours, thereby fostering their proliferation and metastasis, rendering it a pivotal therapeutic target. Nevertheless, to date, no pharmacological agents capable of directly targeting and inducing the degradation of C1QBP have been...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ctm2.70162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586806446522368 |
|---|---|
| author | Xingxing Li Yue Wu Min Zhang Fengliang Wang Hong Yin Yanrong Zhang Shuli Zhao Jiehua Ma Mingming Lv Cheng Lu |
| author_facet | Xingxing Li Yue Wu Min Zhang Fengliang Wang Hong Yin Yanrong Zhang Shuli Zhao Jiehua Ma Mingming Lv Cheng Lu |
| author_sort | Xingxing Li |
| collection | DOAJ |
| description | Abstract C1QBP exhibits heightened expression across a spectrum of tumours, thereby fostering their proliferation and metastasis, rendering it a pivotal therapeutic target. Nevertheless, to date, no pharmacological agents capable of directly targeting and inducing the degradation of C1QBP have been identified. In this study, we have unveiled a new peptide, PDBAG1, derived from the precursor protein GPD1, employing a peptidomics‐based drug screening strategy. PDBAG1 has demonstrated substantial efficacy in suppressing triple‐negative breast cancer (TNBC) both in vitro and in vivo. Its mechanism of action involves mitochondrial impairment and the inhibition of oxidative phosphorylation (OXPHOS), achieved through direct binding to C1QBP, thereby promoting its ubiquitin‐dependent degradation. Concomitantly, due to metabolic adaptability, we have observed an up‐regulation of glycolysis to compensate for OXPHOS inhibition. We observed an aberrant phenomenon wherein the hypoxia signalling pathway in tumour cells exhibited significant activation under normoxic conditions following PDBAG1 treatment. Through size‐exclusion chromatography (SEC) and isothermal titration calorimetry (ITC) assays, we have validated that PDBAG1 is capable of binding C1QBP with a Kd value of 334 nM. Furthermore, PDBAG1 inhibits homologous recombination repair proteins and facilitates synergism with poly‐ADP‐ribose polymerase inhibitors in cancer therapy. This underscores that PDBAG1 ultimately induces insurmountable survival stress through multiple mechanisms while concurrently engendering therapeutic vulnerabilities specific to TNBC. Key points The newly discovered peptide PDBAG1 is the first small molecule substance found to directly target and degrade C1QBP, demonstrating significant tumour inhibitory effects and therapeutic potential. |
| format | Article |
| id | doaj-art-9dcac832a7554851b9d69e8c1b1a6b58 |
| institution | Kabale University |
| issn | 2001-1326 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Medicine |
| spelling | doaj-art-9dcac832a7554851b9d69e8c1b1a6b582025-01-25T04:00:38ZengWileyClinical and Translational Medicine2001-13262025-01-01151n/an/a10.1002/ctm2.70162A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repairXingxing Li0Yue Wu1Min Zhang2Fengliang Wang3Hong Yin4Yanrong Zhang5Shuli Zhao6Jiehua Ma7Mingming Lv8Cheng Lu9Department of Breast Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing ChinaThe State Key Laboratory of Pharmaceutical Biotechnology Division of Immunology Medical School Nanjing University Nanjing ChinaDepartment of Breast Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing ChinaDepartment of Breast Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing ChinaDepartment of Breast Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing ChinaNanjing Women and Children's Healthcare Institute Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing ChinaGeneral Clinical Research Center Nanjing First Hospital Nanjing Medical University Nanjing ChinaNanjing Women and Children's Healthcare Institute Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing ChinaDepartment of Breast Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing ChinaDepartment of Breast Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing ChinaAbstract C1QBP exhibits heightened expression across a spectrum of tumours, thereby fostering their proliferation and metastasis, rendering it a pivotal therapeutic target. Nevertheless, to date, no pharmacological agents capable of directly targeting and inducing the degradation of C1QBP have been identified. In this study, we have unveiled a new peptide, PDBAG1, derived from the precursor protein GPD1, employing a peptidomics‐based drug screening strategy. PDBAG1 has demonstrated substantial efficacy in suppressing triple‐negative breast cancer (TNBC) both in vitro and in vivo. Its mechanism of action involves mitochondrial impairment and the inhibition of oxidative phosphorylation (OXPHOS), achieved through direct binding to C1QBP, thereby promoting its ubiquitin‐dependent degradation. Concomitantly, due to metabolic adaptability, we have observed an up‐regulation of glycolysis to compensate for OXPHOS inhibition. We observed an aberrant phenomenon wherein the hypoxia signalling pathway in tumour cells exhibited significant activation under normoxic conditions following PDBAG1 treatment. Through size‐exclusion chromatography (SEC) and isothermal titration calorimetry (ITC) assays, we have validated that PDBAG1 is capable of binding C1QBP with a Kd value of 334 nM. Furthermore, PDBAG1 inhibits homologous recombination repair proteins and facilitates synergism with poly‐ADP‐ribose polymerase inhibitors in cancer therapy. This underscores that PDBAG1 ultimately induces insurmountable survival stress through multiple mechanisms while concurrently engendering therapeutic vulnerabilities specific to TNBC. Key points The newly discovered peptide PDBAG1 is the first small molecule substance found to directly target and degrade C1QBP, demonstrating significant tumour inhibitory effects and therapeutic potential.https://doi.org/10.1002/ctm2.70162anti‐tumour peptideC1QBPhomologous recombination repairmitochondrial functiontargeted protein degradation |
| spellingShingle | Xingxing Li Yue Wu Min Zhang Fengliang Wang Hong Yin Yanrong Zhang Shuli Zhao Jiehua Ma Mingming Lv Cheng Lu A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair Clinical and Translational Medicine anti‐tumour peptide C1QBP homologous recombination repair mitochondrial function targeted protein degradation |
| title | A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair |
| title_full | A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair |
| title_fullStr | A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair |
| title_full_unstemmed | A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair |
| title_short | A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair |
| title_sort | new peptide inhibitor of c1qbp exhibits potent anti tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair |
| topic | anti‐tumour peptide C1QBP homologous recombination repair mitochondrial function targeted protein degradation |
| url | https://doi.org/10.1002/ctm2.70162 |
| work_keys_str_mv | AT xingxingli anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT yuewu anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT minzhang anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT fengliangwang anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT hongyin anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT yanrongzhang anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT shulizhao anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT jiehuama anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT mingminglv anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT chenglu anewpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT xingxingli newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT yuewu newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT minzhang newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT fengliangwang newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT hongyin newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT yanrongzhang newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT shulizhao newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT jiehuama newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT mingminglv newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair AT chenglu newpeptideinhibitorofc1qbpexhibitspotentantitumouractivityagainsttriplenegativebreastcancerbyimpairingmitochondrialfunctionandsuppressinghomologousrecombinationrepair |